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Abstract 
Infertility is considered a major public health issue, and approximately 1 out of 6 people worldwide suffer from 
infertility during their reproductive lifespans. Thanks to technological advances, genetic tests are becoming increas-
ingly relevant in reproductive medicine. More genetic tests are required to identify the cause of male and/or female 
infertility, identify carriers of inherited diseases and plan antenatal testing. Furthermore, genetic tests provide direc-
tion toward the most appropriate assisted reproductive techniques. Nevertheless, the use of molecular analysis in 
this field is still fragmented and cumbersome. The aim of this review is to highlight the conditions in which a genetic 
evaluation (counselling and testing) plays a role in improving the reproductive outcomes of infertile couples. We 
conducted a review of the literature, and starting from the observation of specific signs and symptoms, we describe 
the available molecular tests. To conceive a child, both partners’ reproductive systems need to function in a precisely 
choreographed manner. Hence to treat infertility, it is key to assess both partners. Our results highlight the increasing 
importance of molecular testing in reproductive medicine.
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Introduction
During the last few decades, there have been a series of 
striking advancements in reproductive and laboratory 
medicine that have essentially caused these two fields to 
become inextricably connected. Laboratory medicine 
now plays a critical role in all stages of the reproductive 
process, from diagnostic approaches to the choice of the 
most complex therapy.
In particular, genetic tests are carried out for three 
main purposes in reproductive medicine: the identifica-
tion of the infertility causes, identification of genetic dis-
eases transmissible to offspring, and optimization of the 
assisted reproductive technology (ART) (Fig. 1).
The overall fertility rate is decreasing; for example, in 
the US, 12% of women receive fertility treatment over 
the course of their lifetimes, so it is important to empha-
size the fertility journey of couples [1]. The reproduc-
tive systems of both partners function in a combined 
and precisely coordinated way to conceive a child; for 
this reason, evaluation of both members of the couple is 
mandatory.
A medical evaluation is indicated when the couple 
fails to achieve pregnancy after 12  months of regular, 
unprotected sexual intercourse [2]. Currently, the diag-
nostic timeline of infertile couples includes biochemical 
and instrumental analyses that allow for a diagnosis in 
65% of cases; in the remaining 35% of cases, which are 
undiagnosed, genetic tests are performed. Considering 
that approximately 15% of genetic disorders are asso-
ciated with infertility and that similar clinical signs can 
have genetic and nongenetic causes, it is important that 
an infertility diagnosis be determined by the combina-
tion of an accurate medical history and instrument- and 
laboratory-based evaluations, including targeted genetic 
tests [3]. Confirmation of the clinical diagnosis through 
genetic evaluation (counselling and testing) can lead to 
more specific and targeted medical management.
In addition, genetic tests are also indicated for the 
identification of genetic diseases that are transmis-
sible to the offspring: preconception screening allows 





2 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, 
Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, 
80131 Naples, Italy
Full list of author information is available at the end of the article
Page 2 of 33Cariati et al. J Transl Med          (2019) 17:267 
their reproductive risk a priori. Normally, gametes with 
genetic or chromosomal alterations have reduced repro-
ductive potential. Thanks to ART, many of these difficul-
ties can be overcome, and therefore, genetic tests (carrier 
screening, preimplantation and prenatal diagnosis) have 
the crucial impact of monitoring the possible transmis-
sion of these genetic alterations to the offspring [4, 5].
Another application field of molecular diagnostics is 
related to the antenatal diagnosis. To date, the diagnos-
tic options for couples at risk of transmitting a specific 
Fig. 1 The three main fields of application for which genetic testing is required to improve reproductive medicine: identification of the infertility 
causes (a), identification of genetic diseases transmissible to offspring (b), and optimization of the assisted reproductive techniques (c)
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inherited disorder to their offspring are preimplanta-
tion genetic testing (PGT) and prenatal diagnosis (PND). 
These two diagnostic procedures share the same pur-
pose but differ in diagnostic time, type of sampling, and 
laboratory procedures. In addition to the more tradi-
tional laboratory investigations, it is now undisputed that 
molecular biology methods for PGT support the efficacy 
of ART techniques, contributing significantly to their 
success (reductions in time, effort and cost) [5, 6].
To optimize the application of genetic tests in clinical 
practice, in this review, we discuss (1) the genetic condi-
tions related to infertility, including the common and rare 
ones that are case appropriate; (2) the diagnostic strate-
gies in families at risk of known monogenic disease trans-
mission; and (3) the impact of PGT in the optimization of 
ART techniques.
Materials and methods
The literature review was carried out according to 
PRISMA guidelines. No temporal restrictions were 
applied. The research was performed using the follow-
ing keywords: genetic cause of infertility, genetic cause of 
male infertility, genetic cause of female infertility, muta-
tions and infertility, molecular diagnostics in infertile 
couples, molecular diagnostics and reproductive medi-
cine, PGT techniques, and PGT and ART. All the papers 
found were carefully read and evaluated before their 
inclusion. No unpublished studies were taken into con-
sideration. In addition, the following databases were also 
consulted to verify gene/phenotype associations: NIH 
(https ://www.nih.gov), OMIM (https ://www.omim.org) 
and OrphaNet (https ://www.orpha .net/conso r/cgi-bin/
index .php).
Results
Genetic tests in the identification of the causes of infertility
It has been estimated that every healthy subject is a car-
rier of 5/8 genetic alterations associated with recessive 
genetic disorders; therefore, even in the absence of spe-
cific symptoms, family planning and reproduction can 
be risky. Moreover, it has been reported that almost 50% 
of infertility cases are related to genetic disorders [7, 8]. 
In the presence or high suspicion of a genetically based 
reproductive risk, the genetic test provides a more accu-
rate diagnosis of infertility and provides the opportunity 
to inform the couple about the possible risk of trans-
mission to the offspring. Unfortunately, genetic tests for 
examining infertility are based on a standard algorithm 
directed to investigate the most frequent genetic causes 
without taking into account the patient’s personal or 
family history. Consequently, the results are quite dis-
couraging: a genetic diagnosis is reached in approxi-
mately 4% of all infertile males, and approximately 20% 
of infertile couples remain undiagnosed. In contrast, an 
accurate medical and familial history aimed at identify-
ing genetically based syndromes (characterized by typical 
dimorphisms, associated disabilities and even infertility) 
could direct patients to specific genetic tests [9]. Starting 
from this consideration, we examined the genetic disor-
ders related to male and female infertility and subdivided 
them according to the signs and symptoms observed by 
the specialist during the first medical examination. Genes 
associated with specific and rare clinical conditions were 
not excluded either; they could be useful, in the context 
of a specific clinical picture, to request an in-depth analy-
sis using a targeted genetic test. Therefore, we provide the 
main points on the genetic pathology, current test execu-
tion modality and management of the patient (Tables 1, 
2, 3, 4, 5, 6, 7).
Male genetic infertility
Genetic factors have been found in all the etiological 
categories of male fertility (pre-testicular, testicular and 
post-testicular): OMIM (Online Mendelian Inheritance 
in Man) reports more than 200 genetic conditions related 
to male infertility, ranging from the most common clini-
cal presentations of infertility to the rarest complex syn-
dromes in which signs and symptoms are beyond the 
reproductive problems [103]. In most cases, infertility 
is only one of the clinical signs of a complex syndrome; 
on the contrary, in some genetic conditions, infertility is 
the main phenotypic feature. Moreover, it is important 
to monitor these infertile patients over time because a 
greater morbidity and a lower life expectancy have been 
described for these infertile patients than for the gen-
eral population and are most likely caused by the genetic 
abnormalities involved in male sterility [104].
Today, the presence of alterations in the spermio-
gram is the first indication for genetic tests, particularly 
in cases of severe oligospermia (< 5 million/ml) (further 
parameters are hormonal levels, malformations, recur-
rent abortions, and family history) [105]. Interestingly, a 
recent study by Oud et  al. highlighted how the number 
of genes that are definitively linked to the more common 
phenotypes of oligozoospermia or azoospermia remains 
limited (50%); the other half are genes involved in terato-
zoospermia, although the monomorphic forms of terato-
zoospermia are extremely rare [106].
Genetic disorders related to male infertility include 
whole chromosomal aberrations (structural or numeri-
cal), partial chromosomal aberrations (i.e., microdele-
tions of the Y chromosome) (listed in Tables  1, 2) and 
monogenic diseases (listed in Tables 3, 4, 5). In particular, 
abnormalities in sex chromosomes have a greater impact 
on spermatogenesis, while mutations affecting autosomes 
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are more related, for example, to hypogonadism, terato-
spermia or asthenozoospermia and to familial forms of 
obstructive azoospermia.
Currently, the main genetic tests routinely used for the 
diagnosis of male infertility are the karyotype, the study 
of chromosome Y microdeletions, and the analysis of 
the CFTR gene. Since it has been reported that several 
mutated are related to male infertility, it is not surprising 
that in ~ 40% of all cases of male infertility, the underly-
ing genetic pathogenesis remains unknown [107, 108]. It 
must also be considered that the role of de novo muta-
tions should be further investigated, especially in light 
of what happens for Klinefelter syndrome and AZF 
deletions that occur almost exclusively de novo [106]. 
Therefore, to improve and personalize the entire diag-
nostic–therapeutic pathway of male infertility, targeted 
genetic tests should be performed in the presence of spe-
cific clinical pictures, always after appropriate genetic 
counselling: (1) for diagnostic purposes, (2) during clini-
cal decision-making to establish the most appropriate 
ART strategy (for example, in the presence of deletions 
of the AZFa and AZFb regions, the possibility of sperm 
recovery using testicular biopsy is extremely low), and (3) 
for prognostic purposes (to establish the risk of transmit-
ting the pathology and plan a prenatal or preimplantation 
diagnostic procedures).
Whole chromosomal aberrations The prevalence of 
chromosomal alterations varies from 1.05 to 17% (this 
gap depends on the characteristics of the studied group) 
but is 0.84% in newborns [109]. Structural chromo-
somal rearrangements are more common with respect to 
numerical abnormalities; this does not apply to sex chro-
mosomes whose abnormalities, accounting for approxi-
mately 4.2% of all whole chromosomal aberrations, are 
represented by sex chromosome aneuploidies in 84% of 
cases and by structural rearrangements of chromosome 
Y in the remaining 16% of cases. Klinefelter syndrome 
(karyotype 47, XXY) is the most frequent type of sex 
chromosome aneuploidy detected in infertile men [11, 
12]; the second most frequent gonosomal abnormality 
is Double Y syndrome or Jacobs syndrome, character-
ized by the presence of Y chromosome disomy [14, 110]. 
In addition to reduced reproductive potential, carriers 
of chromosomal abnormalities have an increased risk of 
abortion or generate a child with an abnormal karyotype. 
For this reason, Table  1 shows the main chromosomal 
aberrations that could interfere with healthy reproduc-
tion, the relative information on the phenotypic aspect, 
the laboratory tests to highlight them and the indications 
for antenatal genetic testing.
Partial chromosomal aberrations Microdeletions in 
the long arm of the Y chromosome (Yq), named the AZF 
(Azoospermia Factor) region, have been found in 8–12% 
of azoospermic men and 3–7% of oligozoospermic men 
[106], resulting in the most common molecular genetic 
cause of male infertility [110]. The AZF region includes 
three groups of genes (AZFa, AZFb and AZFc) that are 
most responsible for spermatogenesis, so partial or 
complete deletions in this area may impair reproduc-
tive capacity. Indications for AZF deletion screening are 
based on sperm count (< 5 × 106 spermatozoa/ml) associ-
ated with primary testiculopathy, and ICSI is required to 
overcome infertility [111].
Male offspring will carry the same father’s Yq microde-
letions or even a worse one; therefore, genetic counsel-
ling is mandatory [112]. Parents should be aware of the 
risk of having a child affected by Turner’s syndrome (45, 
X0) or other phenotypic anomalies associated with sex 
chromosome mosaicism [113].
The rearrangement of the AZFc zone is responsible 
for 60% of all Yq microdeletions [114]. The AZFc region 
(3.5  Mb) contains several copies of five repeats (b1, b2, 
b3, b4, and gr), whose similarity and large size predispose 
an individual to a relatively high incidence of de novo 
deletions via homologous recombination [115]. The most 
common is the loss of the whole b2/b4 region, which 
includes the DAZ family (Deleted in Azoospermia) and 
leads to spermatogenesis deterioration [115, 116]. More 
details about AZF are reported in Table 1.
Single gene mutations This section will focus on the 
noteworthy single gene disorders that have clinical rel-
evance for male infertility (Tables 3, 4, 5). Although thou-
sands of genes are involved in male infertility, today, only 
a handful of genetic diseases are routinely investigated 
(e.g., cystic fibrosis) [117, 118]. As shown by several stud-
ies, the approaches to identify a single causative gene are 
not useful considering that more than 2300 genes are 
expressed in the testis alone and that hundreds of them 
influence reproductive functions and can contribute 
to male infertility. Even if nearly 50% of infertility cases 
are due to single or multiple genetic defects, the genetic 
causes remain unexplained for 20% of patients [3]. Fur-
thermore, the increasingly widespread use of tools, such 
as NGS (next-generation sequencing), for both diagnostic 
and research purposes will allow us to rapidly expand our 
knowledge of this field [4].
Starting from the clinical and laboratory evaluation, as 
shown in Tables 3, 4, 5, the main genetic conditions that 
could interfere with healthy reproduction are reported 
with the aim of improving the targeted genetic test in the 
presence of specific clinical pictures.
Female genetic infertility
In contrast to male infertility, little is known about the 
genetic bases of female infertility. Accordingly, fewer spe-
cific tests are routinely recommended to infertile females 
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to investigate the presence of chromosomal disorders 
or single-gene defects related to their clinical pheno-
types. Indeed, isolated infertility due to genetic causes is 
rare; more commonly, syndromic diseases contribute to 
female infertility. To date, genetic tests are mainly used 
for patients with POI, limited to chromosomal aberra-
tions and FMR1 premutations. We therefore focused 
on the description of these two conditions; however, as 
shown in Tables  6, 7, more details have been reported 
concerning the main chromosomal and genetic altera-
tions that could interfere with healthy reproduction; for 
each of them, the main phenotypic presentations and the 
laboratory tests that are available in the pre- and postna-
tal periods are reported.
Whole chromosomal aberrations Considering that 
chromosomal disorders significantly impact fertility 
and the miscarriage risk, karyotype analysis is always 
advisable [119]. The most clinically important struc-
tural disorders in infertile females are translocations, 
both reciprocal (exchange of two terminal segments 
from different chromosomes) or Robertsonian (centric 
fusion of two acrocentric chromosomes) responsible 
for blocks of meiosis and structural alterations of the X 
chromosome. Patients with reciprocal translocations 
are at a significantly increased risk of infertility, includ-
ing hypogonadotropic hypogonadism with primary or 
secondary amenorrhea or oligomenorrhea. The balanced 
rearrangements do not create health problems for their 
carriers because they cause neither loss nor duplication 
of genetic information, but they can give rise to gametes 
in which the genetic information is unbalanced and can 
thus become a cause of infertility or multiple miscarriage. 
Some abnormalities, such as the XXX karyotype, could 
not be clearly associated with infertility.
Women with a normal karyotype produce a variable 
percentage of oocytes with chromosomal abnormali-
ties due to errors occurring during crossing-over and/or 
meiotic nondisjunction [120, 121]. The three main classes 
of abnormalities are 45X, trisomy and polyploidy. It is 
well known that these events increase with maternal age 
[122]. It is possible to analyze gametes or embryos while 
undergoing ART thanks to PGT. The efficacy of the tech-
nique is increased after screening for aneuploid embryos 
and transferring only euploid embryos [123, 124].
Fragile X syndrome Fragile X syndrome is an autoso-
mal dominant genetic disorder caused by the presence of 
over 200 repetitions of the CGG triplet sequence in the 
FMR1 (Fragile X Mental Retardation 1) gene or by a dele-
tion affecting the FMR2 (Fragile X Mental Retardation 2) 
gene. Carriers of the female FMR1 premutation (when 
the number of CGG repeats falls between 55 and 200) 
or FMR2 microdeletion show menstrual dysfunction, 
diminished ovarian reserve, and premature ovarian fail-
ure [125, 126].
In addition to the family history, in the case of women 
with these clinical manifestations, the possibility of a 
molecular test should be considered. The most common 
genetic contributors to POI are X-chromosome-linked 
defects. In rare cases, the cause is an alteration in an 
autosomal chromosome [88]. Identifying the mutations 
in a timely fashion is of paramount importance to man-
aging the reproductive options and, if necessary, choos-
ing a preimplantation genetic diagnosis program: the aim 
is to identify the specific clinical pictures in which a tar-
geted genetic test could guide a personalized diagnostic–
therapeutic treatment approach.
Molecular approaches in the identification of genetic 
diseases that are transmissible to offspring
It is well known that in 20–25% of cases, perinatal mor-
tality is caused by inherited chromosomal or genetic 
alterations [127]. Thanks to medical awareness in recent 
decades, preconception carrier screening has become 
widely requested. The identification of couples at risk 
of transmitting a specific inherited disorder to their off-
spring offers the possibility of making informed repro-
ductive choices to future parents. If the reproductive 
partner happens to carry a gene alteration for one of the 
genetic conditions, the pregnancy would be at risk for a 
child with that disease.
The American College of Obstetricians and Gynecolo-
gists has issued standard recommendations for ethnic 
and general population genetic screening in couples 
based on reproductive age [128]. Testing is available for 
more than 2000 genetic disorders, including common 
diseases, such as sickle-cell anemia, cystic fibrosis, and 
spinal muscular atrophy, or more complex conditions, 
such as mental retardation and congenital heart disease.
In this context, genetic counselling is crucial for recog-
nizing the genetic risk, referring patients appropriately 
and informing patients about genetic issues that are rel-
evant to decision-making [129]. In fact, preconception 
carrier screening provides genetic information for mul-
tiple disorders; thus, all carrier couples can make repro-
ductive decisions based on their results. The tailored 
genetic test is a crucial tool to improve short-term and 
long-term outcomes for mothers and their babies [130, 
131].
Currently, during the antenatal period, a variety of 
techniques are available to identify a transmissible disor-
der to the offspring in the presence of carrier or affected 
couples. Each of these techniques can be applied only 
during a specific time period of pregnancy or at different 
embryo stages in the IVF protocol.
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Invasive PND is usually performed on DNA extracted 
from fetal cells obtained by chorionic villus sampling 
(CVS) (between the 11th and 13th weeks of gestation) 
or from amniocytes (from the 15th to the 20th week), 
and the result is obtained in 7 or 15  days, respectively 
[132]. The molecular diagnosis for monogenic disease, 
as we detailed in a previous publication, is carried out by 
direct mutation analysis when the parental mutations are 
known or by linkage analysis when the parental muta-
tions are unknown [5, 132]. Paternity verification and 
contamination analysis are always performed in addition 
to the specific analytic phases [5].
An increasing amount of interest has been shown 
regarding the noninvasive prenatal diagnosis (NIPD) 
of monogenic disease that is able to detect fetal genetic 
alterations in maternal blood at an early gestational age 
(approximately 10  weeks). However, although nonin-
vasive prenatal testing (NIPT) of cell-free fetal DNA 
(cffDNA) for the screening of chromosomes 21, 18, 13, X 
and Y has been clinically adopted, NIPD remains a chal-
lenge [133]. Very recently, NIPD for clinical use has been 
adopted in cases of sex-linked disorders and RHD [134]. 
Several studies have tested the application of NIPD in 
monogenic diseases, such as β-thalassemia, congenital 
adrenal hyperplasia, and Duchenne and Becker muscular 
dystrophy [135–137]. The disruptive technology of NGS 
together with the haplotyping strategy is driving the pos-
sibility of using NIPD in clinical cases.
PGT has the same diagnostic motivation as the tradi-
tional PND, with the advantage of advancing the tim-
ing of diagnosis at the embryo stage. Only disease-free 
embryos are transferred to the mother, avoiding recourse 
to therapeutic abortion. Even for couples who are able 
to conceive naturally, PGT requires the application of 
IVF techniques, including (a) the collection of gametes 
from both partners; (b) the fertilization of the oocyte by 
intracytoplasmic sperm injection (ICSI); (c) the embryo 
biopsy, which allows one or more cells from the blasto-
mere or trophectoderm to be taken 3 or 5 days, respec-
tively, postfertilization; (d) molecular analysis and (e) the 
embryo transfer.
PGT protocols are set to start from a small amount of 
biological sample, ranging from 1 to 10 cells from the 
embryo at the cleavage stage or blastocyst stage. Conflict-
ing opinions are reported on the detrimental effects of 
embryo biopsy and mosaicism events between cleavage-
stage and blastocyst embryos. Linan et al. demonstrated 
that the concordance of diagnosis in embryos that were 
double biopsied on D3 and D5 is 67.8% lower than previ-
ously reported, supporting the use of blastocyst biopsies 
instead of cleavage-stage embryo biopsies [138]. Recently, 
data from the Preimplantation Genetic Diagnosis Inter-
national Society (PGDIS) in 2018 showed no difference 
in the detrimental effects between the embryo stages if 
experienced operators performed the biopsies [139, 140].
PGT includes whole genome amplification (WGA) to 
obtain a sufficient quantity of genomic DNA for one or 
more molecular investigations [141, 142]. Several types of 
WGA can be used depending on the downstream applica-
tion [142]. The most used technique for PGT is still rep-
resented by “multiplex polymerase chain reaction” (PCR) 
and capillary electrophoresis analysis for the direct iden-
tification of the causative mutation of the disease and the 
analysis of at least two informative polymorphic mark-
ers [the most used are the “short tandem repeats” (STR), 
microsatellites characterized by short tandem nucleotide 
repeats] or the analysis of at least 3 polymorphic markers 
in the event that the causative mutation is not known [5, 
143]. However, since PGT tailored to a disease is a labori-
ous and expensive procedure, which is time-consuming 
in the preliminary phase for the study of the family, sev-
eral laboratories use genome-wide approaches to analyze 
gene markers throughout the genome. Alan Handyside 
tested “karyomapping” based on a single nucleotide 
polymorphism (SNP) array able to determine the geno-
type of an individual by analyzing thousands of SNPs 
distributed throughout the genome [144]. The “karyo-
mapping” involves a “linkage” analysis: with a compari-
son of the SNPs associated with the causative mutation 
of the disease to be investigated, that are present in the 
index case and that are therefore in the parents’ chro-
mosomes, to the SNPs present in the embryo cells, it is 
possible to identify the presence or absence of the muta-
tion carrier [144–146]. In addition, the density of the 
SNPs allows a higher resolution in the case of crossings 
between chromosomes close to the mutated gene. Finally, 
it is possible to use “karyomapping” in families with com-
binations of more monogenic alterations or that require 
HLA compatibility, truly demanding investigations to be 
carried out with conventional methods. “Karyomapping”, 
however, loses its effectiveness when it is not possible 
to establish which parental allele is linked to the genetic 
alteration; for quantitative analysis of mitotic abnormali-
ties (mosaicisms), “karyomapping” does not directly ana-
lyze the mutation and cannot detect de novo mutations. 
The aim of most new approaches is to use a targeted SNP 
analysis to detect single mutations or groups of common 
mutations combined with quantitative haplotype analysis 
or chromosome count. Recently, a genome-wide protocol 
using NGS has been tested for the identification of family 
mutations together with cytogenetic screening in embryo 
biopsies [147–149]. The protocol is based on an enlarged 
panel of disease-associated genes (approximately 5000 
genes) and enables, in a single workflow, (a) the direct 
detection of family mutations and the indirect detection 
through linkage analysis of heterozygous SNPs (PGT-M); 
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(b) a chromosomal translocation (PGT-SR) analysis; and 
(c) testing for aneuploidies. However, the limitations of a 
single NGS protocol are related to its inability to detect 
haploidies, polyploidies, and mosaicisms. In addition, the 
analysis of consanguineous families is not recommended. 
Finally, other limitations regarding the limit of detection 
or the size of the translocation supported by the protocol 
could be overcome using haplotyping in the presence of 
the index case.
Molecular approaches for the optimization of art 
techniques
Human embryos that are developed in vitro show a great 
deal of acquired chromosomal abnormalities; for this rea-
son, PGT for aneuploidy (PGT-A) has been developed to 
select euploid embryos that are suitable for transfer [150].
PGT-A is primarily indicated for couples with advanced 
maternal age, recurrent implantation failure, recurrent 
abortions, or severe male infertility. Meiotic errors are 
one of the main causes of the low success rate (~ 30%) 
of in  vitro fertilization techniques. Randomized studies 
and meta-analyses have shown that the PGT-A technique 
does not increase the live birth rate but decreases the 
miscarriage rate and increases the efficiency of IVF tech-
niques [123, 151].
The evolution of PGT-A techniques started with a lim-
ited number of chromosomes analyzed by fluorescence 
in  situ hybridization (FISH) in 1995 [152]. It was soon 
overcome by the analysis of the whole chromosome set 
by using different genetic platforms, such as metaphase 
Comparative Genomic Hybridization (mCGH), array-
based Comparative Genomic Hybridization (aCGH), 
single nucleotide polymorphism (SNP) microarray, quan-
titative polymerase chain reaction (qPCR), and, most 
recently, NGS.
Currently, the most commonly used technique is NGS. 
This method involves the amplification of the genome 
from a single cell by WGA, the preparation of a DNA 
library, starting directly from the amplified DNA, and 
the subsequent sequencing of a pool of libraries in par-
allel, each identified by a specific “barcode” sequence. 
Finally, an analysis software that compares the sequences 
obtained in each sample with respect to the “human hap-
map reference genome” allows the identification of the 
possible presence of chromosome aneuploidies [153]. 
Literature data confirm that NGS can be successfully 
applied to the diagnosis of a variety of genetic abnormali-
ties, even in single cells isolated from human embryos 
following WGA, and has numerous advantages over the 
technologies traditionally used for PGT-A [153–156].
However, it was soon clear that the gold standard was 
to develop a method for the analysis of both mono-
genic diseases and PGT-A at the same time. Indeed, as 
previously discussed, the very recent innovation for this 
purpose is the use of NGS to analyze single gene muta-
tions and chromosomal copy number variations to select 
euploid disease-free embryos [157]. Currently, only a 
novel mutation continues to be a challenge [140].
Discussion
Healthy reproduction can be affected by unhealthy envi-
ronmental and lifestyle factors, increasing paternal and/
or maternal age, anatomical or genetic anomalies, sys-
temic or neurological diseases, infections, trauma, and 
antibody development [158, 159]. As a consequence, 
infertility can be the result of nongenetic and genetic fac-
tors, and it is often multifactorial, polygenic or a com-
bination of both. Presumably, hundreds of genes must 
interact in a precise manner during sex determination, 
gametogenesis, complex hormone actions/interactions, 
embryo implantation, and early development to generate 
healthy offspring. Indeed, known genetic causes of infer-
tility include chromosomal aberrations, single gene vari-
ants and phenotypes with multifactorial inheritance. To 
date, specific genes and mutations have been confirmed 
to be associated with infertility phenotypes in males, 
females or both, and our knowledge regarding the molec-
ular basis of infertility is continually growing. Confirma-
tion of a clinical diagnosis through genetic testing may 
lead to personalized medical management. Similar clini-
cal symptoms may be the result of different genetic varia-
tions. Specifically, in more rare clinical situations, genetic 
evaluations (counseling and testing) can contribute to the 
specific identification of the disease or to the confirma-
tion of a suspected diagnosis. The combination of the 
detailed clinical information provided and the identified 
genetic cause will allow the development of a personal-
ized diagnostic–therapeutic strategy.
The first stage in assessing a couple with potential fertil-
ity problems involves the substantial synergy between the 
patient’s medical history, physical examination, instru-
mentation analysis (pelvic ultrasound in women) and 
laboratory tests (sperm analysis in males) to identify any 
underlying pathology and possible risk factors. Although 
this evaluation should be performed simultaneously for 
both partners, the male partner analysis is required only 
in 18% of cases [160]. Figure  2 shows how the integra-
tion of couples’ information can stratify patients on the 
basis of different morpho-functional aspects and outline 
already differential diagnostic–therapeutic approaches. 
When a complete and simultaneous assessment of the 
couple is not performed, the fertility prognosis is com-
promised, and the opportunity to improve the health 
outcomes of each subject is lost. For this reason, it is 
essential to accurately collect, for each member of the 
couple, data regarding the personal history (life habits, 
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smoking, alcohol use, drug use, sports activities, etc.) and 
the medical history (genital characteristics at birth and 
in the first years of life, pubertal development, and any 
past disease affecting the genital system). The medical 
history evaluation must focus on the presence of possi-
ble metabolic, endocrine, and genetic disorders with the 
aim of highlighting elements that can lead to subsequent, 
specific diagnostic tests. At this stage, it is important to 
identify patients who can benefit from predictive genetic 
testing: the use of targeted multigene panels can become 
a useful tool that, by allowing the identification of further 
causes of infertility, may improve genetic and reproduc-
tive counselling and patient stratification. In fact, some 
cases of infertility are due to unknown genetic mutations; 
for this reason, collecting data is mandatory to increase 
the detection rate (which is currently 80%) and to reduce 
the percentage of idiopathic infertility.
Many couples learn that they are at high risk of hav-
ing a child that is affected by a genetic disease only when 
the woman is already pregnant or after giving birth. 
Thus, a detailed family history for a couple planning to 
undergo ART is a useful tool for identifying genetically 
at-risk couples and can improve the medical care of these 
patients. A number of important factors must be con-
sidered when collecting a detailed family history in the 
context of family planning [129]. These include the his-
tory of the patient’s pregnancy (e.g., multiple abortions 
may indicate a chromosomal abnormality), the degree of 
kinship (particular attention should be given to first- and 
second-degree relatives who may have a history of men-
tal retardation, learning difficulties, progressive muscle 
weakness, early cataracts, infertility, motionless birth, 
recurrent miscarriages, and coagulation disorders), the 
consanguinity of the couple [129], and the ethnicity of 
Fig. 2 Stratifying the population, through the identification of risk factors and diseases that may be present, allows the organization of targeted 
diagnostic–therapeutic approaches. The couples in which the reproductive risk is lower are those in which an unhealthy lifestyle was evident in 
the absence of pathological conditions; in this case, it is necessary to take action based on this information to promote a healthy lifestyle. The 
reproductive risk increases in couples in which, during the diagnostic phase, the presence of a disease in only one of the partners is identified. In 
both cases, there are specific interventions aimed at the patient. However, targeted interventions are required in couples with a high reproductive 
risk, i.e., when both partners are affected by a pathology and after the failure of all methods to achieve pregnancy naturally
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both groups of grandparents. Furthermore, references to 
other specialists (e.g., fetal maternal medicine, reproduc-
tive endocrinology, gynecology) should be considered to 
exclude maternal/paternal infertility causes. In the case 
of identification of pathologies, in one or both partners, 
standard diagnostic algorithms will be used, while in 
specific situations, integration will need to be made with 
specific diagnostic procedures that require integration 
with eligibility criteria to access ART.
NGS-based strategies offer the opportunity not only to 
optimize genetic testing in reproductive medicine (since 
in one step, it may be possible to analyze the potential 
causes of infertility, perform carrier screening, and sup-
port ART) but also to tailor the therapeutic decision on 
the basis of the specific genomic features of the patients. 
Common observation reveals that patients with the same 
diagnosis may respond differently to therapies, and it 
is becoming increasingly evident that this differential 
responsiveness may be due to specific DNA variations at 
the genomic level. The challenge for future medicine is 
to move from a population-based view to an individually 
based one. Novel technologies are driving this revolu-
tion. In the context of reproductive medicine, for exam-
ple, it has been established that specific single nucleotide 
variants in the genes encoding for hormonal receptors 
are able to influence the efficacy of hormonal therapies 
in inducing ovulation [161]. In addition, other molecu-
lar features of the patients should be taken into account 
before starting therapeutic protocols to avoid potential 
side effects. An opportunity comes from the example of 
the BRCA test. Indeed, BRCA1 and BRCA2 are the most 
common genes related to hereditary breast and ovarian 
cancers. Molecular screening for these genes has greatly 
increased in recent years due to technological simplifica-
tion and the availability of specific drugs that are suitable 
for patients with mutations in these genes. As a conse-
quence, several affected and nonaffected young females 
have been found to be carriers of a BRCA mutation. This 
information should be taken into account when repro-
ductive choices are planned, considering the potential 
risk of treating these patients with hormonal therapy.
Conclusions
Currently, both the entire diagnostic pathway and the 
effectiveness of genetic analysis for infertility suffer 
from an approach that is ineffective: only a few genetic 
variables are studied, each through a specific molecu-
lar diagnostic procedure. This makes the process of 
genetic investigation fragmented and cumbersome, 
with a negative impact on the couple, in addition to the 
psychological distress caused by infertility. Therefore, 
despite the large potential of genetic tests to provide 
real insights into infertility causes, this crucial tool is 
still used without a method tailored to diagnostic needs 
regarding infertility. However, recent developments in 
new sequencing technologies have made it possible to 
compact one or more tests into a single NGS-based 
analysis, thus reducing diagnostic costs and time. The 
European Society of Human Genetics (ESHG) and the 
European Society of Human Reproduction and Embry-
ology (ESHRE) have recently issued a recommendation 
for the development and introduction of extended car-
rier screening [162]. Although it is difficult to predict at 
this time how much the diagnostic yield of genetic tests 
for the different subtypes of male and female infertility 
will increase, it is realistic to expect a decrease in the 
current percentage of idiopathic infertility.
The general state of health in the reproductive envi-
ronment is gaining increasing attention and clinical 
relevance. Therefore, reproductive specialists have the 
task of evaluating infertile couples by considering both 
their general and reproductive health, since the relative 
conditions of comorbidity can influence their repro-
duction. Medicine is undergoing an important trans-
formation from a reactive to a preventive approach: the 
future will focus on the integrated diagnosis, treatment 
and prevention of diseases in individual patients.
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